This week in Drug Discovery (10 – 14 November)
News round-up for 10 – 14 November by Bruno Quinney, Content Team at DDW.
This week’s top story comes from groundbreaking research showing the Covid-19 mRNA vaccine boosts the immune system’s cancer response. The theme of UK investment dominates other headlines, while a report shows an effective treatment for ALS could be worth billions.
The top stories:
Covid mRNA boosts cancer response, study shows
Research showing the Covid-19 mRNA vaccine boosts the immune system’s response to cancer has been described as ‘extraordinary’.
Read more…
ABPI urges UK government to stop life sciences ‘falling behind’
In a statement submitted this week, the Association of the British Pharmaceutical Industry (ABPI) urged the UK government to revive its investment in the life sciences sector.
Initiative aims to replace animal models for drug development
The UKRI Medical Research Council (MRC), Wellcome and UKRI Innovate UK committed a joint £15.9 million ($20.9 million) investment to develop advanced, specific and highly reproducible human in vitro models.
UK commits to major regulatory reform for rare therapies
The rulebook for rare disease therapies will be overhauled to make it quicker and easier to get these therapies tested, manufactured and approved in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced.
ALS treatment could be worth billions, research suggests
New research commission by Challenge Works and undertaken by the Office of Health Economics (OHE) estimates that a successful treatment for ALS, the most common form of motor neurone disease (MND), could be worth billions.
Read more…
